Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
This report aims to provide a comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics. This report contains market size and forecasts of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in global, including the following market information:
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market was valued at US$ 7854.6 million in 2022 and is projected to reach US$ 11030 million by 2030, at a CAGR of 5.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
We surveyed the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Segment Percentages, by Type, 2022 (%)
Oral Therapy
Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, market overview.
Chapter 2: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Overall Market Size
2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size: 2022 VS 2030
2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players in Global Market
3.2 Top Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies Ranked by Revenue
3.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Markets, 2022 & 2030
4.1.2 Oral Therapy
4.1.3 Injectable Therapy
4.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2024-2030
4.2.3 By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2022 & 2030
5.1.2 Hospitals & Clinics
5.1.3 Home Settings
5.1.4 Ambulatory Surgical Centers (ASCs)
5.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2024-2030
5.2.3 By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2024-2030
6.2.3 By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2030
6.3.2 US Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.3.3 Canada Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.3.4 Mexico Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2030
6.4.2 Germany Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4.3 France Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4.4 U.K. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4.5 Italy Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4.6 Russia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.4.8 Benelux Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2030
6.5.2 China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.5.3 Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.5.4 South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.5.6 India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2030
6.6.2 Brazil Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.6.3 Argentina Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2030
6.7.2 Turkey Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.7.3 Israel Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
6.7.5 UAE Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, 2018-2030
7 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies Profiles
7.1 Astellas Inc.
7.1.1 Astellas Inc. Company Summary
7.1.2 Astellas Inc. Business Overview
7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Major Product Offerings
7.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Astellas Inc. Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Major Product Offerings
7.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 Sanofi S.A
7.3.1 Sanofi S.A Company Summary
7.3.2 Sanofi S.A Business Overview
7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Major Product Offerings
7.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Sanofi S.A Key News & Latest Developments
7.4 Dendreon Corporation
7.4.1 Dendreon Corporation Company Summary
7.4.2 Dendreon Corporation Business Overview
7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Major Product Offerings
7.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Dendreon Corporation Key News & Latest Developments
7.5 Bayer AG
7.5.1 Bayer AG Company Summary
7.5.2 Bayer AG Business Overview
7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Major Product Offerings
7.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Bayer AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Opportunities & Trends in Global Market
Table 2. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers in Global Market
Table 3. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints in Global Market
Table 4. Key Players of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in Global Market
Table 5. Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Type
Table 9. List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. Astellas Inc. Company Summary
Table 31. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Offerings
Table 32. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. Astellas Inc. Key News & Latest Developments
Table 34. Johnson & Johnson Company Summary
Table 35. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Offerings
Table 36. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Johnson & Johnson Key News & Latest Developments
Table 38. Sanofi S.A Company Summary
Table 39. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Offerings
Table 40. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Sanofi S.A Key News & Latest Developments
Table 42. Dendreon Corporation Company Summary
Table 43. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Offerings
Table 44. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Dendreon Corporation Key News & Latest Developments
Table 46. Bayer AG Company Summary
Table 47. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Offerings
Table 48. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Bayer AG Key News & Latest Developments
List of Figures
Figure 1. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Segment by Type in 2022
Figure 2. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Segment by Application in 2022
Figure 3. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2022
Figure 8. By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 16. US Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 28. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
